DDInter448 DDInter1676
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Crizotinib {u} (Compound) treats {v} (Disease) lung cancer
Crizotinib {u} (Compound) binds {v} (Gene) MET
Crizotinib {u} (Compound) upregulates {v} (Gene) COL11A1
Crizotinib {u} (Compound) is included by {v} (Pharmacologic Class) Organic Cation Transporter 2 Inhibitors
Crizotinib {u} (Compound) downregulates {v} (Gene) WDR77
Crizotinib {u} (Compound) causes {v} (Side Effect) Dizziness postural
Crizotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Crizotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Crizotinib (Compound) treats lung cancer (Disease)
Crizotinib (Compound) binds MET (Gene)
Crizotinib (Compound) upregulates COL11A1 (Gene)
Crizotinib (Compound) is included by Organic Cation Transporter 2 Inhibitors (Pharmacologic Class)
Crizotinib (Compound) downregulates WDR77 (Gene)
Crizotinib (Compound) causes Dizziness postural (Side Effect)
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib